{
    "id": 17921,
    "fullName": "NRAS E63K",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "NRAS E63K does not lie within any known functional domains of the Nras protein (UniProt.org). E63K confers a loss of function on Nras protein as demonstrated by increased GTP-bound Nras leading to activation of downstream signaling, and is associated with resistance to Egfr inhibitors in culture (PMID: 25870145).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4893,
        "geneSymbol": "NRAS",
        "terms": [
            "NRAS",
            "ALPS4",
            "CMNS",
            "N-ras",
            "NCMS",
            "NRAS1",
            "NS6"
        ]
    },
    "variant": "E63K",
    "createDate": "02/13/2016",
    "updateDate": "09/20/2018",
    "referenceTranscriptCoordinates": {
        "id": 162429,
        "transcript": "NM_002524",
        "gDna": "chr1:g.114713903C>T",
        "cDna": "c.187G>A",
        "protein": "p.E63K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4477,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18231,
                "profileName": "EGFR exon 19 del NRAS E63K"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4478,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18231,
                "profileName": "EGFR exon 19 del NRAS E63K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4476,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18231,
                "profileName": "EGFR exon 19 del NRAS E63K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18230,
            "profileName": "NRAS E63K",
            "profileTreatmentApproaches": [
                {
                    "id": 16519,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "NRAS E63K"
                },
                {
                    "id": 16518,
                    "name": "PIK3CA inhibitor",
                    "profileName": "NRAS E63K"
                },
                {
                    "id": 16520,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "NRAS E63K"
                },
                {
                    "id": 16521,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "NRAS E63K"
                },
                {
                    "id": 16517,
                    "name": "MEK2 Inhibitor",
                    "profileName": "NRAS E63K"
                },
                {
                    "id": 16522,
                    "name": "MEK1 Inhibitor",
                    "profileName": "NRAS E63K"
                }
            ]
        },
        {
            "id": 18231,
            "profileName": "EGFR exon 19 del NRAS E63K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 162429,
            "transcript": "NM_002524",
            "gDna": "chr1:g.114713903C>T",
            "cDna": "c.187G>A",
            "protein": "p.E63K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}